1. Home
  2. XLO vs QNCX Comparison

XLO vs QNCX Comparison

Compare XLO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • QNCX
  • Stock Information
  • Founded
  • XLO 2016
  • QNCX 2012
  • Country
  • XLO United States
  • QNCX United States
  • Employees
  • XLO N/A
  • QNCX N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XLO Health Care
  • QNCX Health Care
  • Exchange
  • XLO Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • XLO 37.9M
  • QNCX 44.0M
  • IPO Year
  • XLO 2021
  • QNCX 2019
  • Fundamental
  • Price
  • XLO $0.75
  • QNCX $0.99
  • Analyst Decision
  • XLO Buy
  • QNCX Strong Buy
  • Analyst Count
  • XLO 1
  • QNCX 5
  • Target Price
  • XLO $4.00
  • QNCX $8.00
  • AVG Volume (30 Days)
  • XLO 233.4K
  • QNCX 134.5K
  • Earning Date
  • XLO 05-13-2025
  • QNCX 05-12-2025
  • Dividend Yield
  • XLO N/A
  • QNCX N/A
  • EPS Growth
  • XLO N/A
  • QNCX N/A
  • EPS
  • XLO N/A
  • QNCX N/A
  • Revenue
  • XLO $6,344,000.00
  • QNCX N/A
  • Revenue This Year
  • XLO $668.96
  • QNCX N/A
  • Revenue Next Year
  • XLO $14.49
  • QNCX N/A
  • P/E Ratio
  • XLO N/A
  • QNCX N/A
  • Revenue Growth
  • XLO N/A
  • QNCX N/A
  • 52 Week Low
  • XLO $0.62
  • QNCX $0.51
  • 52 Week High
  • XLO $1.70
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • XLO 50.44
  • QNCX 25.41
  • Support Level
  • XLO $0.63
  • QNCX $0.93
  • Resistance Level
  • XLO $0.80
  • QNCX $1.04
  • Average True Range (ATR)
  • XLO 0.06
  • QNCX 0.10
  • MACD
  • XLO 0.01
  • QNCX -0.02
  • Stochastic Oscillator
  • XLO 72.93
  • QNCX 13.47

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Share on Social Networks: